-
Joseph von Mering and Oskar Minkowski Discover the Role of the Pancreas in Diabetes
Two French researchers Oskar Minkowky and Joseph Von Mering found the removal of pancreas could lead to diabetes and German scienctist Georg Zuelzer claimed that pancreatic extract would control diabetes -
Sir Edward Albert Sharpey-Schafer Proposed Calling the Chemical Deficiency in Diabetics within the Pancreas 'Insulin'
In 1910, Sir Edward Albert Sharpey-Schafer suggested that people with diabetes were deficient in a single chemical that was normally produced by the pancreas—he proposed calling this substance insulin, from the Latin insula, meaning island, in reference to the insulin-producing islets of Langerhans in the pancreas. -
First Edition of The Treatment of Diabetes Mellitus
Famous Boston scientist named Elliot Joslin published his first edition of The Treatment of Diabetes Mellitus, which highlighted the importance of regular exercises and a fasting diet in self-management of diabetes -
Insulin is Discovered
Federick Banting, M.D. and his assistant Charles Best, M.D successfully treat diabetes by extracting insulin from dog pancreas and injecting it into two other dogs without pancreas. James Collip then later purified this hormone in order to use in human. All these scientist has been awarded Nobel Prize in Medicine -
The First Insulin Injection was given to Leonard Thompson
Researcher John Macleod and chemist James Collip then began to help prepare insulin for human use. On January 11, 1922, Leonard Thompson, a 14-year-old boy who was dying of diabetes, was given the first human experimental dose of insulin. The injection indeed lowered his blood sugar and cleared his urine of sugars and other signs of the disease. Banting and Best published the first paper on their discovery a month later, in February, 1922. -
John James Richard Macleod and Frederick Grant Banting are Awarded the Nobel Prize in Medicine for the Discovery of Insulin
Determined to investigate this possibility, Banting discussed it with various people, among whom was J.J.R. Macleod, Professor of Physiology at the University of Toronto, and Macleod gave him facilities for experimental work upon it. -
Sir Harold Percival Himsworth Distinguishes Between Type 1 and Type 2 Diabetes
The distinction between what is now known as type 1 diabetes and type 2 diabetes was first clearly made by Sir Harold Percival (Harry) Himsworth, and published in January 1936. -
Marcel Janbon Discovers the Antidiabetic Effects of Sulfonylureas by Chance
Sulfonylureas, on the other hand, are effective in controlling type 2 di abetes. Marcel J. Janbon discovered the antidiabetic effects of sulfony lureas in 1942 by chance. -
FDA Approves Lilly's Humulin N
Humulin N is an insulin injection for patients with type 1 and type 2 diabetes. Humulin N is a replicated version of human insulin hormone that is intended to treat diabetes symptoms up to 24 hours post-injection. -
FDA Approves Pfizer's Glucotrol
Glucotrol is an oral diabetes medicine that helps control blood sugar levels. This medication helps your pancreas produce insulin. Glucotrol is used together with diet and exercise to treat type 2 (non-insulin dependent) diabetes. -
FDA Approves Bristol-Myers Squibb's Glucophage
Glucophage is an oral diabetes medicine that helps control blood sugar levels.It is used for people with type 2 (non-insulin-dependent) diabetes. Glucophage is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes. -
FDA Approves Bayer's Precose
Precose is a glucosidase inhibitor. It works by slowing down the enzyme that turns carbohydrates into glucose. This decreases blood sugar levels following a meal. Along with diet and exercise or with other antidiabetic medicines, this medicine is used to treat type 2 diabetes -
FDA Approves Sanofi Aventis's Amaryl
AMARYL (glimepiride tablets) is an oral blood-glucose-lowering drug of the sulfonylurea class. This medication helps your body respond better to insulin produced by your pancreas. It is used together with diet and exercise to treat type 2 (non-insulin dependent) diabetes. Insulin or other diabetes medicines are sometimes used in combination with this medicine if needed. -
FDA Approves Lilly's Humalog
Humalog is an insulin analog that is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. -
FDA Approves Pharmacia and UpJohn's Glyset
Glyset is used as an add-on treatment to diet to improve high blood sugar levels caused by type 2 diabetes mellitus. Glyset may also be used in combination with a sulfonylurea (such as Glipizide, Glimepiride, or Glyburide) when diet plus either Glyset or a sulfonylurea alone do not result in adequate blood sugar control. -
FDA Approves Novo Nordisk's Prandin
Prandin lowers blood sugar by causing the pancreas to produce insulin. It is used together with diet and exercise to treat type 2 (non-insulin dependent) diabetes. Other diabetes medicines are sometimes used in combination with repaglinide if needed -
FDA Approves SB Pharmco's Avandia
Avandia is an oral diabetes medicine that helps control blood sugar levels by making the cells of the body more sensitive to the action of insulin. It is used for people with type 2 (non-insulin-dependent) diabetes. It is sometimes used in combination other medications, but it is not for treating type 1 diabetes. Taking Avandia with insulin or nitrates is not recommended. -
FDA Approves Takeda's Actos
Actos is for people with type 2 (non-insulin-dependent) diabetes. It is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes. -
FDA Approves Daiichi Sankyo's Welchol
WelChol is used to lower blood cholesterol levels when diet and exercise prove insufficient. It works by binding with cholesterol-based bile acids to take them out of circulation. This prompts the liver to produce a replacement supply of bile acids, drawing the extra cholesterol it needs out of the bloodstream. -
FDA Approves Sanofi Aventis's Lantus
Lantus (insulin glargine) is a man-made form of a natural hormone. It is a long-acting insulin that is slightly different from other forms of insulin that are not man-made and it works by lowering levels of glucose in the blood. This medication is used to treat type 1 (insulin-dependent) or type 2 (non insulin-dependent) diabetes. -
FDA Approves Novartis's Starlix
Starlix combats high blood sugar levels in people with type 2 diabetes (the kind that does not require insulin shots). Insulin speeds the transfer of sugar from the bloodstream to the body's cells, where it's burned to produce energy. -
FDA Approves Metformin
It is the first-line drug of choice for the treatment of type 2 diabetes, particularly in overweight and obese people and those with normal kidney function.Evidence is also mounting for its efficacy in gestational diabetes, although safety concerns still preclude its widespread use in this setting. It is also used in the treatment of polycystic ovary syndrome and has been investigated for other diseases where insulin resistance may be an important factor. -
FDA Approves Deltec's Cozmo Insulin Pump
The Deltec Cozmo pump is the first to integrate a blood glucose monitor with the actual pump. They communicate with each other and make figuring corrections with insulin faster and easier. -
FDA Approves Amylin's Symlin
It is designed to mimic the activity of the naturally occurring hormone amylin, which is secreted together with insulin and is involved in post-prandial glucose control.
Symlin is specifically indicated for the mealtime treatment of Type I and Type II diabetes in combination with standard insulin therapy, in patients who have failed to achieve adequate glucose control on insulin monotherapy. It can be administered to type II diabetics also on metformin or sulfonylurea therapy. -
FDA Approves Amylin's Byetta
Type 2 Diabetes Mellitus BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. If you have type 2 diabetes, a healthcare provider may prescribe Byetta to help lower blood sugar levels. The drug comes in the form of an injection. The injection is given twice a day and is administered just under the skin of the thigh, abdomen, or upper arm. -
Disentronic's Accu-Chek Spirit Insulin Pump Launches
ACCU-CHEK® diabetes care products are among the world’s best. Combine that with a history of innovation and you have a recipe for insulin pump therapy success. -
FDA Approves Merck's Januvia
JANUVIA is a once-daily pill that helps lower blood sugar levels in adults with type 2 diabetes. It works to help your body do 2 things:
1. Increase the insulin made by your pancreas when blood sugar is high,
2. Reduce the amount of sugar made by your liver.
It is not likely to cause weight gain. -
FDA Approves Merck's Janumet
JANUMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate. -
FDA Approves Medtronic's OneTouch UltraLink Meter
Medtronic, Inc. today announced that the FDA has cleared the OneTouch® UltraLink™ Meter as the new wireless meter exclusively certified by Medtronic to wirelessly communicate with Medtronic diabetes management products in the United States. -
FDA Approves Bristol-Myers Squibb's Onglyza
Onglyza works by enhancing the body's natural ability to control high blood sugar. It can be used alone or together with one of several common oral diabetes medicines, such as metformin, a thiazolidinedione (TZD), or a sulfonylurea. Onglyza (saxagliptin) is for people with type 2 diabetes (non-insulin-dependent) diabetes. It is sometimes used in combination with other diabetes medications, but is not for treating type 1 diabetes. -
FDA Approves Novo Nordisk's Victoza
The FDA has approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in adults. Victoza is intended to help lower blood sugar levels along with diet, exercise, and selected other diabetes medicines. It isn't recommended as the first therapy patients try if they haven't adequately controlled their diabetes with diet and exercise alone. -
FDA Approves Medtronic's MiniMed Paradigm Real-Time Revel System
This state-of-the-art system gives you the control of an insulin pump plus real-time glucose monitoring. The MiniMed Paradigm Real-Time Revel System helps you take immediate corrective or preventative action to keep your glucose levels healthy and prevent diabetes-related complications. -
American Diabetes Association Endorses New Aspirin Guidelines for Diabetic Patients
The new recommendations are based on close examination of nine studies that found the risks of some aspirin side effects, such as stomach bleeding, should be better balanced against the possible benefits of using aspirin.The new guidelines suggest low-dose aspirin therapy be used by men over 50 and women over 60 with diabetes who have other risk factors for heart attack and stroke. -
Tel Aviv University Study Finds Diabetes Doubles Cancer Risk in Women
The researchers at Tel Aviv University's Department of Epidemiology and Preventive Medicine at the Sackler Faculty of Medicine observed 16,721 diabetics, differentiating between men and women and defining the relative cancer risks for each group. Type 2 diabetes appears to reduce the risk of prostate cancer in men, but appears to increase the risk of some cancers in women, researchers in Israel said. -
Rosemary Dray-Spira Finds Link Between Higher Educational Attainment and Lower Mortality Rates in Diabetic Patients
The mortality risk among adults with diabetes differs greatly by educational level, and although the relative disparities in this population are not as strong as those in adults without diabetes, their absolute impact is greater, according to a study in the June issue of Diabetes Care. -
Study Published in the Journal of Agricultural and Food Chemistry Finds Drinking Coffee Lowers Risk of Diabetes
The study, published in the Journal of Agricultural and Food Chemistry, shows that coffee improves insulin sensitivity and helps prevent the development of high blood sugar - at least in lab mice. Drinking coffee, a lots of it, may help prevent type 2 diabetes, a disease affecting millions and on the rise across the globe, according to a new study published in the American Chemical Society's Journal of Agricultural and Food Chemistry. -
Harvard University Study Finds Replacing White Rice with Brown Rice Lowers Diabetes
Now a new study from researchers at Harvard reports that Americans who eat two or more servings of brown rice a week reduce their risk of developing Type 2 diabetes by about 10 percent compared to people who eat it less than once a month.And those who eat white rice on a regular basis — five or more times a week — are almost 20 percent more likely to develop Type 2 diabetes than those who eat it less than once a month. -
Anti-VEGF Therapy Introduced
Ranibizumab, brand name Lucentis (Genentech), was approved for treatment of diabetic macular edema. It works by inhibiting a protein called “vascular endothelial growth factor” (VEGF). In 2015, this treatment was approved for diabetic retinopathy in patients who have diabetic macular edema. The drug is injected into the eye monthly and helps prevent the excess blood vessel growth that can lead to blindness in people with diabetes. -
FDA approves Invokana (Canagliflozin)
The first in a new class of drugs know as the SGLT-2 inhibitors, for lowering elevated blood sugar in patients with type 2 diabetes. SGLT-2 inhibitors block the activity of sodium glucose transport proteins in the kidney, reducing glucose re-uptake and increasing secretion of glucose in the urine. -
All Pregnant Women Advised to Be Tested for Diabetes
The USPSTF issued a final recommendation advising all pregnant women be screened for gestational diabetes after 24 weeks of pregnancy. The screening was issued a “B” rating, meaning health insurers were required to cover the screening at no cost to the patient. -
Diabetes Complications Reduced
A study published in the New England Journal of Medicine reported that the incidence of diabetes complications dramatically improved as a result of research advances and preventive care over the course of 20 years (1990-2010). Among people with diabetes, the study showed a 52.9% reduction in stroke; 67.8% reduction in acute myocardial infarction; 51.4% reduction in amputation; 28.3% reduction in end stage renal disease and 64.4% reduction in hyperglycemic crisis deaths.
